Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 8/20 | 0.53 |
| ▸ | HTR7 | P34969 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirenperone SCHEMBL10965711 | 0.99 | HTR2C (0.98) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| Pirenperone SCHEMBL10967003 | 0.96 | HTR2C (0.93) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| Pirenperone SCHEMBL10970070 | 0.96 | HTR2C (0.93) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| Pirenperone SCHEMBL11242425 | 0.94 | CYP2D6 (0.89) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| SCHEMBL17532707 | 0.93 | CYP2D6 (0.86) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| SCHEMBL10967011 | 0.92 | CYP2D6 (0.86) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| SCHEMBL6527939 | 0.87 | HTR2C (0.77) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| Metrenperone SCHEMBL2109868 | 0.87 | HTR2C (0.77) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| SCHEMBL6522324 | 0.86 | HTR2C (0.76) | HTR2CCYP2D6KDM4EMAPTTSHR | |
| SCHEMBL10963572 | 0.86 | CYP2D6 (0.75) | HTR2CCYP2D6KDM4EMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 597 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4680244-A1 | SEROTONIN 5HT2A RECEPTOR ANTAGONIST FOR USE IN TREATING SIDE EFFECTS RESULTING FORM MU OPIOID RECEPTOR AGONIST OVERDOSE | Norwegian University Of Life Sciences (NO) | 2026-01-21 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| WO-2024194263-A1 | SEROTONIN 5HT2A RECEPTOR ANTAGONIST FOR USE IN TREATING SIDE EFFECTS RESULTING FORM MU OPIOID RECEPTOR AGONIST OVERDOSE | NORWEGIAN UNIVERSITY OF LIFE SCIENCES (NO) | 2024-09-26 | — | — | WO | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2006018538-A1 | MEDICAMENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | GREENPHARMA (FR) | 2006-02-23 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2002036114-A1 | COMPOSITION COMPRISING SEROTONIN RECEPTOR ANTAGONISTS, 5 HT-2 AND 5 HT-3 | RESPIRATORIUS AB (SE) | 2002-05-10 | — | — | WO | claimed |
| EP-1014928-A2 | USE OF A SEROTONIN ANTAGONIST OR AGONIST RESPECTIVELY SPECIFIC OF THE 5HT 2? AND 5HT 1D? RECEPTOR IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND RESULTING COMPOSITION | L'OREAL (FR) | 2000-07-05 | — | — | EP | claimed |
| WO-1998031335-A2 | USE OF A SEROTONIN ANTAGONIST AND/OR AGONIST RESPECTIVELY SPECIFIC OF THE 5HT2 AND 5HT1D RECEPTOR IN A COSMETIC OR DERMATOLOGICAL COMPOSITION FOR SENSITIVE SKIN AND RESULTING COMPOSITION | L'OREAL (FR) | 1998-07-23 | — | — | WO | claimed |
| EP-0037265-B1 | 3-(1-PIPERIDINYLALKYL)-4H-PYRIDO(1,2-A)PYRIMIDIN-4-ONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-01-23 | — | — | EP | claimed |
| US-4342870-A | SEROTONIN ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-08-03 | — | — | US | claimed |
| EP-0037265-A1 | 3-(1-piperidinylalkyl)-4H-pyrido(1,2-a)pyrimidin-4-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-10-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | HTR2C 5/4885CYP2D6 84/4885KDM4E 291/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | HTR2C 5/4885CYP2D6 1202/4885KDM4E 2780/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | HTR2C 5/4885CYP2D6 928/4885KDM4E 4347/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR2C 2/4885CYP2D6 2262/4885KDM4E 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.